In Vitro Maturation (IVM) for Polycystic Ovary Syndrome (PCOS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01237106
Recruitment Status : Completed
First Posted : November 9, 2010
Last Update Posted : December 3, 2015
Information provided by (Responsible Party):
Peter McGovern, MD, University Reproductive Associates

Brief Summary:

This pilot study will be a prospective investigation to study the efficacy and safety of In-Vitro Maturation (IVM) for women with Polycystic Ovarian Syndrome (PCOS). There will be 10 subjects total in this Study. There will be no blinding to treatment.

In-Vitro Maturation will provide a viable, safe option for women with PCOS attempting pregnancy through the use of Assisted Reproductive Technology (ART).

Condition or disease Intervention/treatment Phase
Polycystic Ovarian Syndrome Other: IVM Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: In Vitro Maturation for Polycystic Ovary Syndrome (PCOS)- A Pilot Study
Study Start Date : November 2010
Actual Primary Completion Date : February 2012
Actual Study Completion Date : November 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: In Vitro Maturation (IVM) Other: IVM
all patients in this pilot study will undergo IVM. IVM involves immature eggs being retrieved and matured in the laboratory.After maturation they are fertilized like is done in a typical IVF cycle.

Primary Outcome Measures :
  1. Incidence of Biochemical Pregnancy (defined as a rising Beta-HCG level). [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. number of immature oocytes retrieved [ Time Frame: 6 months ]
  2. rates of maturation and fertilization [ Time Frame: 6 months ]
  3. Incidence of Ovarian Hyperstimulation Syndrome (OHSS) [ Time Frame: 6 months ]
  4. live births [ Time Frame: 1 1/2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 34 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria

  1. 10 women between the ages of 18-34 inclusive at time of signing Informed Consent Form.
  2. A diagnosis of PCOS by their primary MD
  3. An Antral Follicular Count (AFC) of > 12 on one ovary on at least one occasion
  4. A day 3 FSH level of <8 IU/mL
  5. In good general health off of current medications which may confound response to study medications.
  6. Desire to seek pregnancy actively during the study period by IVF-ICSI.
  7. A normal uterine cavity must have been confirmed by either hydrosonogram or hysteroscopy within two years of entering the study.
  8. Male partner able to provide adequate semen sample by ejaculation (no TESE)

Exclusion Criteria

  1. Current pregnancy
  2. Patients with uncorrected thyroid disease (defined as TSH < 0.2 mIU/ML or >5.5 mIU/mL). A normal level within the last year is adequate for entry.
  3. Patients with poorly controlled diabetes (HgB A1C over 8.0 ng/dL).
  4. Patients enrolled simultaneously into other investigative studies that require medications, proscribe the study medications, limit intercourse, or otherwise prevent compliance with the protocol.
  5. Patients with significant anemia (Hemoglobin < 10 mg/dL).
  6. Patients enrolled simultaneously into other investigative studies that would interfere with this research study.
  7. have any contraindications to using birth control pills (oral contraceptives) as determined by the attending physician (e.g. history of thromboembolism or estrogen-dependent malignancy, such as breast cancer, etc.) -

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01237106

United States, New Jersey
University Reproductive Associates
Hasbrouck Heights, New Jersey, United States, 07604
University Reproductive Associates
Hoboken, New Jersey, United States, 07030
Sponsors and Collaborators
University Reproductive Associates
Principal Investigator: Peter G. McGovern, MD Rutgers, The State University of New Jersey

Responsible Party: Peter McGovern, MD, Medical Director, University Reproductive Associates Identifier: NCT01237106     History of Changes
Other Study ID Numbers: IRB 0120100297
First Posted: November 9, 2010    Key Record Dates
Last Update Posted: December 3, 2015
Last Verified: December 2015

Keywords provided by Peter McGovern, MD, University Reproductive Associates:
Polycystic ovarian syndrome
In Vitro Maturation

Additional relevant MeSH terms:
Polycystic Ovary Syndrome
Pathologic Processes
Ovarian Cysts
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases